Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome

Journal of Interventional Cardiology

Volumn 24, Issue 3, 2011, Pages 199-207

  Ramaraj, Radhakrishnan ^a   Movahed, Mohammad Reza ^a   Hashemzadeh, Mehrnoosh ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; CREATININE; HEPARIN; HIRULOG; PLACEBO; PRASUGREL; TICAGRELOR; URIC ACID; WARFARIN;

ACUTE CORONARY SYNDROME; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; DYSPNEA; HEART MUSCLE ISCHEMIA; HOMEOSTASIS; HUMAN; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SIDE EFFECT; STENT THROMBOSIS; STRUCTURE ACTIVITY RELATION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBUS; VEIN THROMBOSIS;

ACUTE CORONARY SYNDROME; ADENOSINE; HUMANS; PURINERGIC P2Y RECEPTOR ANTAGONISTS;

EID: 79959830774     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2010.00613.x     Document Type: Article

References (39)

1. Hashemzadeh M, Goldsberry S, Furukawa M, et al. ADP receptor-blocker thienopyridines: Chemical structures, mode of action and clinical use. A review. J Invasive Cardiol 2009;21:406-412.
2. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015. (Pubitemid 350106708)
3. Hoffman M, Monroe DM. Coagulation 2006: A modern view of hemostasis. Hematol Oncol Clin North Am 2007;21:1-11.
4. Coppinger JA, Cagney G, Toomey S, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004;103:2096-2104. (Pubitemid 38326225)
5. Pitsilos S, Hunt J, Mohler ER, et al. Platelet factor 4 localization in carotid atherosclerotic plaques: Correlation with clinical parameters. Thromb Haemost 2003;90:1112-1120. (Pubitemid 38004432)
6. Koyama H, Maeno T, Fukumoto S, et al. Platelet P-selectin expression is associated with atherosclerotic wall thickness in carotid artery in humans. Circulation 2003;108:524-529. (Pubitemid 36961164)
7. Fateh-Moghadam S, Li Z, Ersel S, et al. Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2. Arterioscler Thromb Vasc Biol 2005;25:1299-1303. (Pubitemid 40776625)
8. Nowak J,Murray JJ, Oates JA, et al. Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 1987;76:6-14. (Pubitemid 17093187)
9. Davi G, Averna M, Catalano I, et al. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation 1992;85:1792-1798.
10. Davi G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl JMed 1990;322:1769-1774. (Pubitemid 20194655)
11. Minuz P, Patrignani P, Gaino S, et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 2002;106:2800-2805. (Pubitemid 35396979)
12. Di Minno G, Davi G, Margaglione M, et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 1993;92:1400-1406. (Pubitemid 23273917)
13. Davi G, Gresele P, Violi F, et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997;96:69-75. (Pubitemid 27298406)
14. Davies MJ. Stability and instability: Two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation 1996;94:2013-2020. (Pubitemid 26349317)
15. Dubois C, Panicot-Dubois L, Gainor JF, et al. Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. J Clin Invest 2007;117:953-960. (Pubitemid 46556751)
16. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995;92:657-671.
17. Harrington RA, Becker RC, Ezekowitz M, et al. Antithrombotic therapy for coronary artery disease: The Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:513S-548S.
18. Menon V, Harrington RA, Hochman JS, et al. Thrombolysis and adjunctive therapy in acute myocardial infarction: The Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:549S-575S.
19. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166-1173.
20. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008;29:21-30.
21. Kuliczkowski W, Witkowski A, Polonski L, et al. Interindividual variability in the response to oral antiplatelet drugs: A position paper of theWorking Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009;30:426-435.
22. Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis:Adouble-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-1047.
23. Khoynezhad A, Movahed MR, Hashemzadeh M, et al. Perioperative management of patients on adenosine diphosphate inhibitors in the era of drug-eluting stents: Review of the literature and clinical implications. Curr Med Chem 2009;16:591-598.
24. James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009;157:599-605.
25. Hashemzadeh M, Furukawa M, Goldsberry S, et al. Chemical structures and mode of action of intravenous glycoprotein IIb/IIIa receptor blockers: A review. Exp Clin Cardiol 2008;13:192-197.
26. Springthorpe B, Bailey A, Barton P, et al. From ATP to AZD6140: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett 2007;17:6013-6018. (Pubitemid 47446193)
27. van Giezen JJJ. Optimizing platelet inhibition. Eur Heart J Suppl 2008;10:D23-D29.
28. Zhan C, Yang J, Dong XC, et al. Molecular modeling of purinergic receptor P2Y12 and interaction with its antagonists. J Mol Graph Model 2007;26:20-31.
29. BrownRA, SpinaD, PageCP. Adenosine receptors and asthma. Br J Pharmacol 2008;153(Suppl 1):S446-S456.
30. Lerman BB, Belardinelli L. Cardiac electrophysiology of adenosine. Basic and clinical concepts. Circulation 1991;83: 1499-1509.
31. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002;105:1348-1353. (Pubitemid 34260427)
32. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): A randomised double-blind study. Lancet;375:283-293.
33. Cannon CP,Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007;50:1844-1851. (Pubitemid 350007959)
34. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
35. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. (Pubitemid 32758501)
36. Serebruany VL. Platelet inhibitionwith prasugrel and increased cancer risks: Potential causes and implications. Am J Med 2009;122:407-408.
37. Biondi-Zoccai G, Lotrionte M, Agostoni P, et al. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol 2010, in press.
38. Schomig A. Ticagrelor-is there need for a new player in the antiplatelet-therapy field? N Engl J Med 2009;361:1108-1111.
39. Bhatt DL. Intensifying platelet inhibition-navigating between Scylla and Charybdis. N Engl J Med 2007;357:2078-2081. (Pubitemid 350106717)